Britain poised to approve Wegovy Pill within days, offering daily alternative to injections.

A transformative weight-loss pill known as the Wegovy Pill could receive official approval in Britain within days, according to recent reports. Sources close to Novo Nordisk, the Danish pharmaceutical developer, confirm that health officials are poised to grant the greenlight soon. This daily tablet represents a convenient alternative to the currently popular once-weekly Wegovy injection.

The Medicines and Healthcare products Regulatory Agency (MHRA) will make the final licensing decision, potentially allowing millions of Britons to access this treatment. However, immediate availability on the National Health Service remains uncertain. The National Institute for Health and Care Excellence (NICE) must first conduct a rigorous appraisal before the drug qualifies for public health service use.

Experts predict that significantly more people will utilize the Wegovy Pill compared to existing injectable options like Mounjaro. Cost plays a pivotal role in this projected shift, as the pill version is expected to be cheaper than its injection counterparts. This pricing advantage could drive widespread adoption among patients seeking effective weight management solutions.

Recent studies indicate that similar weight-loss medications might reduce breast cancer risk by nearly a third. Such findings underscore the broader public health implications of expanding access to these advanced treatments. Government regulators must balance innovation with fiscal responsibility while ensuring equitable distribution across diverse communities.

In the United States, the Wegovy pill carries a price tag of approximately £225 per month, whereas the injectable version costs roughly £260. Despite these figures, significant barriers remain for many patients who hesitate to start weight-loss therapy due to the necessity of self-administering injections. Reports indicate that the oral formulation is expected to receive regulatory approval from health officials soon, a development that could reshape the landscape of obesity treatment.

Polling data from digital healthcare provider Numan reveals that twice as many Britons express a willingness to take a weight-loss pill compared to an injection. This preference is driven by a substantial number of individuals who fear needles, with research suggesting that around one in five potential patients avoid medication due to this anxiety. Currently, an estimated 1.6 million adults in the UK utilize GLP-1 injections, while a further 3.3 million are considering this treatment option.

Dr Tsolmon Tsogbayar, senior clinical product lead at Numan, highlighted the importance of this shift in administration. He noted that many people have sought weight support for years but struggled with the concept of injectable therapy, sometimes avoiding healthcare settings entirely. The introduction of oral GLP-1 medication represents a significant step forward, potentially making evidence-based obesity treatment accessible to a much wider group of patients who previously felt excluded from current options.

The oral Wegovy contains the same active ingredient, semaglutide, as the injection but differs in delivery method. Clinical trials demonstrate that obese patients taking the tablets can lose up to 16.6 per cent of their body weight. While slightly less effective than the injections, which can trigger a reduction of up to 20.7 per cent at the highest dose, the pill offers a distinct advantage in convenience. According to Novo Nordisk, the medication is taken once daily and must be swallowed on an empty stomach with a small amount of water.

Semaglutide functions by reducing appetite through the mimicry of a hormone released in the gut after eating. This mechanism reduces hunger sensations and helps patients feel fuller for longer periods. The drug received approval from the US Food and Drug Administration last December, leading to more than 170,000 patients now taking it daily. Novo Nordisk previously described the pill as a convenient alternative to the injection, with chief executive Mike Doustdar stating that patients will have a once-daily option that helps them lose as much weight as the original Wegovy injection.

Following the approval of the Wegovy Pill, attention is expected to shift toward a rival medication developed by Eli Lilly, the manufacturer of Mounjaro. This drug, named Orforglipron and marketed under the brand name Foundayo, has also delivered promising results in clinical trials. Studies indicate that patients taking the highest 36mg dose lost an average of 11.2 per cent of their body weight over 72 weeks. The drug was approved in the US in April, with a decision on its use in Britain set for a later date, which would provide more pill options for UK adults.